Spero Therapeutics (SPRO) Debt to Equity (2016 - 2024)
Spero Therapeutics (SPRO) has disclosed Debt to Equity for 9 consecutive years, with $0.0 as the latest value for Q3 2024.
- For the quarter ending Q3 2024, Debt to Equity fell 82.81% year-over-year to $0.0, compared with a TTM value of $0.0 through Sep 2024, down 82.81%, and an annual FY2023 reading of $0.0, down 35.62% over the prior year.
- Debt to Equity was $0.0 for Q3 2024 at Spero Therapeutics, down from $0.0 in the prior quarter.
- Across five years, Debt to Equity topped out at $0.02 in Q1 2022 and bottomed at $0.0 in Q3 2024.
- Average Debt to Equity over 5 years is $0.0, with a median of $0.0 recorded in 2020.
- The sharpest move saw Debt to Equity skyrocketed 1171.64% in 2022, then crashed 92.71% in 2023.
- Year by year, Debt to Equity stood at $0.0 in 2020, then increased by 16.6% to $0.0 in 2021, then decreased by 19.12% to $0.0 in 2022, then crashed by 35.62% to $0.0 in 2023, then crashed by 75.62% to $0.0 in 2024.
- Business Quant data shows Debt to Equity for SPRO at $0.0 in Q3 2024, $0.0 in Q2 2024, and $0.0 in Q1 2024.